The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | Current research into JAK inhibitors – specifially ruxolitinib, pacritinib, and momelotinib
Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses research into JAK inhibitors for myelofibrosis, specifically ruxolitinib, pacritinib, and momelotinib. Ruxolitinb demonstrated positive results in the COMFORT-II trials (NCT00934544), reducing splenomegaly and symptom improvement. Similar results were also seen with pacritinib. There is still no to data on momelotinib from the most recent clinical Phase III trial. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
